| SB-TEMPUS |
SB-TEMPUS |
92%
|
Under the Data License Agreement, SB Tempus paid the Company ¥ 7.5 billion ($ 47.9 million) in exchange for the license to an initial records batch, which is recorded in deferred revenue and will be … |
| SB-TEMPUS-CORP |
SB-TEMPUS-CORP |
85%
|
development and commercialization of AI Applications; • our ability to maintain and grow our datasets, including in new disease areas and geographies; • any expectation that the growth of our dataset… |
| TEMPUS-COMPASS-LLC |
TEMPUS-COMPASS-LLC |
85%
|
ing period. In addition to TIME, the Company provides other clinical trial services conducting or supporting studies. Tempus Compass LLC, a subsidiary of the Company, is a contract research organizat… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
Reciprocal relationship from FLGT graph: Reciprocal relationship from TEM graph: Reciprocal relationship from FLGT graph: supplier of the next generation sequencers and associated reagents we use to … |
| GH |
Guardant Health, Inc. |
72%
|
who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the extent their therapeutic relies on a … |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from TEM graph: Reciprocal relationship from GH graph: Reciprocal relationship from TEM graph: Reciprocal relationship from GH graph: Re… |
| IQV |
IQVIA Holdings Inc. |
72%
|
Reciprocal relationship from IQV graph: Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are ru… |
| IQV |
IQVIA Holdings Inc. |
72%
|
who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the extent their therapeutic relies on a … |
| MS-PK |
Morgan Stanley |
72%
|
arrant was automatically cancelled and terminated for no consideration as AstraZeneca declined to extend its financial commitment before December 31, 2024. See Note 15 for further information. On Dec… |
| MS-PK |
Morgan Stanley |
72%
|
Reciprocal relationship from MS-PK graph: Reciprocal relationship from TEM graph: Reciprocal relationship from MS-PK graph: Reciprocal relationship from TEM graph: arrant was automatically cancelled … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the extent their therapeutic relies on a … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are r… |
| NEO |
NeoGenomics, Inc. |
72%
|
Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory tes… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RXRX graph: Reciprocal relationship from TEM graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from TEM graph: e us to successfully deliver results … |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
e us to successfully deliver results over 98% of the time, assuming tissue is received that meets the minimum requirements we have outlined for our assays. Our investments have allowed us to continuo… |
| EKO-DEVICES-INC |
EKO-DEVICES-INC |
62%
|
Inc. and PaigeAI. In cardiology we may compete with companies such as HeartFlow Inc. and Eko Devices, Inc. We expect other competitors to enter this market, including academic medical centers who dev… |
| FOUNDATION-MEDICINE-INC |
FOUNDATION-MEDICINE-INC |
62%
|
iotech and pharmaceutical companies who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the e… |
| HEARTFLOW-INC-ANUMANA-INC |
HEARTFLOW-INC-ANUMANA-INC |
62%
|
cations products include Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Illumina, Inc., and others, with respect to our TO test, and Myriad Genetics, Inc., Caris Life Sciences, and… |
| ROCHE-HOLDINGS-INC-CARIS-LIFE-SCIENCES-GUARDANT- |
ROCHE-HOLDINGS-INC-CARIS-LIFE-SCIENCES-GUARDANT- |
62%
|
iotech and pharmaceutical companies who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the e… |
| ROCHE-HOLDINGS-INC-INTEGRATED-DNA-TECHNOLOGIES |
ROCHE-HOLDINGS-INC-INTEGRATED-DNA-TECHNOLOGIES |
62%
|
applicable requirements necessary for federal and state licenses and accreditation for clinical diagnostic laboratories, including policies and procedures related to patient and employee safety, haza… |
| SENGINE-PRECISION-MEDICINE-LLC |
SENGINE-PRECISION-MEDICINE-LLC |
62%
|
ts, which increased from approximately 218,700 tests for the year ended December 31, 2023 to approximately 270,800 tests for the year ended December 31, 2024. Additionally, there was an increase in a… |
